Correspondence 0001104659-26-017097 from Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc.
Date: Feb. 18, 2026 · CIK: 0001875558 · Accession: 0001104659-26-017097
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293459
Letter
Re: Nuvectis Pharma, Inc.
February 18, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
File No. 333-293459
Ladies and Gentlemen:
Nuvectis Pharma, Inc. (the “Company”) hereby requests, pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective at 4:30 p.m. EST on February 20, 2026, or as soon thereafter as practicable.
Please contact Matt Mamak of Alston & Bird LLP, the Company’s counsel, at (212) 210-1256, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.
Nuvectis Pharma, Inc.
By: /s/ Ron Bentsur
Name: Ron Bentsur
Title: Chairman, Chief Executive Officer and President
Show Raw Text
CORRESP
1
filename1.htm
February 18, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Nuvectis Pharma, Inc.
Registration Statement on Form S-3
File No. 333-293459
Ladies and Gentlemen:
Nuvectis Pharma, Inc. (the
“Company”) hereby requests, pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as
amended, that the effective date of the above-referenced Registration Statement be accelerated so as to permit it to become effective
at 4:30 p.m. EST on February 20, 2026, or as soon thereafter as practicable.
Please contact Matt Mamak
of Alston & Bird LLP, the Company’s counsel, at (212) 210-1256, as soon as the Registration Statement has been declared effective,
or if you have any other questions or concerns regarding this matter.
Nuvectis Pharma, Inc.
By:
/s/ Ron Bentsur
Name:
Ron Bentsur
Title:
Chairman, Chief Executive Officer and President